American Association for Cancer Research
00085472can193108-sup-230159_2_supp_6186345_q7t9tb.pdf (8.77 MB)

Supplementary Data from IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment

Download (8.77 MB)
journal contribution
posted on 2023-03-31, 03:03 authored by Jonathan M. Harnoss, Adrien Le Thomas, Mike Reichelt, Ofer Guttman, Thomas D. Wu, Scot A. Marsters, Anna Shemorry, David A. Lawrence, David Kan, Ehud Segal, Mark Merchant, Klara Totpal, Lisa M. Crocker, Kathryn Mesh, Monika Dohse, Margaret Solon, Zora Modrusan, Joachim Rudolph, Hartmut Koeppen, Peter Walter, Avi Ashkenazi

Supplementary Data, including Supplementary Materials and Methods, References for Supplementary Data, and Figs. S1 to S5 including Figure Legends



Cancer cells exploit the unfolded protein response (UPR) to mitigate endoplasmic reticulum (ER) stress caused by cellular oncogene activation and a hostile tumor microenvironment (TME). The key UPR sensor IRE1α resides in the ER and deploys a cytoplasmic kinase–endoribonuclease module to activate the transcription factor XBP1s, which facilitates ER-mediated protein folding. Studies of triple-negative breast cancer (TNBC)—a highly aggressive malignancy with a dismal posttreatment prognosis—implicate XBP1s in promoting tumor vascularization and progression. However, it remains unknown whether IRE1α adapts the ER in TNBC cells and modulates their TME, and whether IRE1α inhibition can enhance antiangiogenic therapy—previously found to be ineffective in patients with TNBC. To gauge IRE1α function, we defined an XBP1s-dependent gene signature, which revealed significant IRE1α pathway activation in multiple solid cancers, including TNBC. IRE1α knockout in TNBC cells markedly reversed substantial ultrastructural expansion of their ER upon growth in vivo. IRE1α disruption also led to significant remodeling of the cellular TME, increasing pericyte numbers while decreasing cancer-associated fibroblasts and myeloid-derived suppressor cells. Pharmacologic IRE1α kinase inhibition strongly attenuated growth of cell line–based and patient-derived TNBC xenografts in mice and synergized with anti-VEGFA treatment to cause tumor stasis or regression. Thus, TNBC cells critically rely on IRE1α to adapt their ER to in vivo stress and to adjust the TME to facilitate malignant growth. TNBC reliance on IRE1α is an important vulnerability that can be uniquely exploited in combination with antiangiogenic therapy as a promising new biologic approach to combat this lethal disease. Pharmacologic IRE1α kinase inhibition reverses ultrastructural distension of the ER, normalizes the tumor vasculature, and remodels the cellular TME, attenuating TNBC growth in mice.

Usage metrics

    Cancer Research